A Small Psychedelics Player Just Filed New Patents and Dosed Its First Real Patients
Clearmind Medicine (Nasdaq: CMND) hadn't shown up in our patent tracker or trials tracker before now — a gap in our coverage, not a new company. Two real developments this month: on Sept 11, the company enrolled its first actual alcohol-use-disorder patients (at Hadassah Medical Center in Jerusalem) in a trial of CMND-100, its oral formulation of MEAI — a non-hallucinogenic, psychedelic-derived compound distinct from any classic psychedelic, working through serotonergic and alpha-2-adrenergic receptors rather than the 5-HT2A pathway behind classic psychedelic effects. Then on Sept 23, the company disclosed three new US patent applications covering combinations of LSD, ketamine, and ibogaine with N-acylethanolamines (like PEA) — developed with NeuroThera Labs, aimed at depression, PTSD, pain, and substance-use disorders.
Company-reported figures put its broader portfolio at 19 patent families and 32 granted patents as of June 2026. We independently verified one — a MEAI-covering patent (US 12,357,590, "Binge Behavior Regulators") expiring Dec 3, 2037 — and have added the company to both trackers with that verification status noted plainly rather than taking the full portfolio figure on faith.
This is business and clinical-trial reporting, not medical advice. CMND-100 remains investigational and is not FDA-approved for any use.